Supplementary Figures 1-12 from Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN-γ&lt;sup&gt;+&lt;/sup&gt;IL-17&lt;sup&gt;+&lt;/sup&gt; Polyfunctional T Cells That Mediate Rejection of Murine Tumors